New Frontiers in Myelofibrosis Care Presented at ASH 2024
By Claire Harrison, MD, FRCP, FRCPath - Last Updated: February 4, 2025Claire Harrison, MD, of Guy’s and St. Thomas’ NHS Foundation Trust, provides expert insight on the latest advancements in myelofibrosis treatment presented at the 66th American Society of Hematology Annual Meeting & Exposition. She discusses the efficacy of elritercept as a monotherapy and in combination with ruxolitinib, exploring how these approaches may improve outcomes for patients. Dr. Harrison also highlights promising data on other novel compounds shaping the future of myelofibrosis care.
Advertisement
Post Tags:ASH 2024: MF
Advertisement
Related Posts
During The HemOnc Pulse Live! Nick Short, MD gave a presentation on unanswered questions in ALL.
The agent is designed to be an option for cases where CAR T-cell therapies or first-generation bispecifics are unsuccessful.
Mice treated with CLK3 TCR9-T cells had a significantly lower tumor burden than those who received control treatments.
Kelly Chien, MD, discusses how disparities in access to care, resources, and molecular testing impact outcomes in AML.
In the US, a BLA submitted for these two particular combinations is currently under review at the FDA.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.